Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Sep 28

PMID 34575958

Citations 10

Authors

Jasna Klen

Vita Dolzan

Affiliations

Soon will be listed here.

Abstract

SGLT2 (sodium-glucose cotransporter 2) inhibitors are a new class of antihyperglycaemic drugs that act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes mellitus type 2 and their cardiovascular and renal safety have been extensively investigated and confirmed in clinical trials. However, inter-individual differences in response to treatment with SGLT2 inhibitors may present in everyday clinical practice, and good predictors of glycemic response and the risk for adverse events in an individual patient are lacking. As genetic variability of SGLT2 may influence the treatment response, pharmacogenetic information could support the choice of the most beneficial treatment strategy in an individual patient. This review focuses on the clinical and genetic factors that may influence the treatment response to SGLT2 inhibitors in type 2 diabetes patients with comorbid conditions.

Citing Articles

Impact of SGLT2 inhibitors on lower limb complications: a mendelian randomization perspective.

Chen B, Huang M, Pu B, Dong H Front Pharmacol. 2024; 15:1401103.

PMID: 39355774 PMC: 11442421. DOI: 10.3389/fphar.2024.1401103.

The Impact of Genetic Polymorphisms on the Anti-Hyperglycemic Effect of Dapagliflozin.

Wang Z, Li X, Xu Q, Yao Y, Li X, Yan H Diabetes Metab Syndr Obes. 2024; 17:2881-2894.

PMID: 39100970 PMC: 11298192. DOI: 10.2147/DMSO.S464671.

Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases.

Sanz-Canovas J, Ricci M, Cobos-Palacios L, Lopez-Sampalo A, Hernandez-Negrin H, Vazquez-Marquez M Rev Cardiovasc Med. 2024; 24(2):36.

PMID: 39077405 PMC: 11273146. DOI: 10.31083/j.rcm2402036.

Metabolic disorders in prediabetes: From mechanisms to therapeutic management.

Ping W, Hu S, Su J, Ouyang S World J Diabetes. 2024; 15(3):361-377.

PMID: 38591088 PMC: 10999048. DOI: 10.4239/wjd.v15.i3.361.

SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study.

Wang Z, Wei J, Zhao W, Shi R, Zhu Y, Li X Lipids Health Dis. 2024; 23(1):84.

PMID: 38509588 PMC: 10953263. DOI: 10.1186/s12944-024-02072-6.

References

Onder C, Gursoy K, Kuskonmaz S, Kocer U, Culha C . Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes. J Diabetes. 2019; 11(5):348-350. DOI: 10.1111/1753-0407.12896. View

Lan N, Fegan P, Yeap B, Dwivedi G . The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019; 6(5):927-935. PMC: 6816235. DOI: 10.1002/ehf2.12505. View

Verma S, Mazer C, Fitchett D, Inzucchi S, Pfarr E, George J . Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia. 2018; 61(8):1712-1723. PMC: 6061159. DOI: 10.1007/s00125-018-4644-9. View

Cianciolo G, De Pascalis A, Capelli I, Gasperoni L, Di Lullo L, Bellasi A . Mineral and Electrolyte Disorders With SGLT2i Therapy. JBMR Plus. 2019; 3(11):e10242. PMC: 6874177. DOI: 10.1002/jbm4.10242. View

Drexel H, Leiherer A, Saely C, Brandtner E, Geiger K, Vonbank A . Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis. Biosci Rep. 2019; 39(8). PMC: 6684948. DOI: 10.1042/BSR20190299. View

Garcia-Ropero A, Badimon J, Santos-Gallego C . The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018; 14(12):1287-1302. DOI: 10.1080/17425255.2018.1551877. View

Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M . SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol. 2018; 14(11):1113-1121. DOI: 10.1080/17425255.2018.1541348. View

Ordelheide A, Bohm A, Kempe-Teufel D, Wagner R, Machicao F, Heni M . Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations. PLoS One. 2017; 12(5):e0177148. PMC: 5417681. DOI: 10.1371/journal.pone.0177148. View

van den Heuvel L, Assink K, Willemsen M, Monnens L . Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet. 2002; 111(6):544-7. DOI: 10.1007/s00439-002-0820-5. View

10.

Calado J, Soto K, Clemente C, Correia P, Rueff J . Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum Genet. 2003; 114(3):314-6. DOI: 10.1007/s00439-003-1054-x. View

11.

Kenny H, Abel E . Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019; 124(1):121-141. PMC: 6447311. DOI: 10.1161/CIRCRESAHA.118.311371. View

12.

Jackson A, Dewan P, Anand I, Belohlavek J, Bengtsson O, de Boer R . Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation. 2020; 142(11):1040-1054. PMC: 7664959. DOI: 10.1161/CIRCULATIONAHA.120.047077. View

13.

Cherney D, Heerspink H, Frederich R, Maldonado M, Liu J, Pong A . Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020; 63(6):1128-1140. PMC: 7228910. DOI: 10.1007/s00125-020-05133-4. View

14.

Kanai Y, Lee W, You G, Brown D, Hediger M . The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994; 93(1):397-404. PMC: 293794. DOI: 10.1172/JCI116972. View

15.

Wells R, Pajor A, Kanai Y, Turk E, Wright E, Hediger M . Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol. 1992; 263(3 Pt 2):F459-65. DOI: 10.1152/ajprenal.1992.263.3.F459. View

16.

Scheen A . Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2014; 75(1):33-59. DOI: 10.1007/s40265-014-0337-y. View

17.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

18.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

19.

Fediuk D, Nucci G, Dawra V, Cutler D, Amin N, Terra S . Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clin Pharmacokinet. 2020; 59(8):949-965. PMC: 7403171. DOI: 10.1007/s40262-020-00875-1. View

20.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View